IDH2 and cholangiocarcinoma: In terms of IDH2 mutation, there are ongoing clinical trials on the application of the IDH2 inhibitor enasidenib (AG-221) (NCT02273739) and the pan-IDH inhibitor vorasidenib (AG-881), which inhibit IDH1 and IDH2 simultaneously in the treatment of CCA [24].